FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid a looming patent cliff ...
Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...
A US-based subsidiary of Cipla has recalled more than 400 cartons of a generic anti-cancer medication after a manufacturing problem was identified by the United States Food and Drug Administration. (1 ...
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Apotex Inc. Logo ...
Apotex has launched the first generic version of Tasigna ® (nilotinib capsules). Nilotinib is a kinase inhibitor indicated for the treatment of adult and pediatric patients aged 1 year and older with ...
Cipla has got final approval from the USFDA for New Drug Application (NDA) for its Nilotinib Capsules 50 mg, 150 mg and 200 mg respectively. Nilotinib is an FDA approved drug used for the treatment of ...
Azurity Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with ...
Danziten, a nilotinib formulation, approved by FDA for chronic myeloid leukemia without mealtime restrictions, enhancing adherence. Danziten offers equivalent efficacy to Tasigna, with improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results